Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed, HER2-positive advanced and/or metastatic breast cancer not amenable to curative therapy
At least one measurable lesion according to RECIST
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Baseline left ventricular ejection fraction (LVEF) at least 50%
You may not be if
Pregnant, lactating, or women of childbearing potential who are not surgically sterile or not willing to use adequate contraceptive methods
Previous treatment with Herceptin or other anti-HER therapies, or any previous chemotherapy for advanced or metastatic disease
Past medical history significant for any cardiac or central nervous system (CNS) disorders
Poor hematologic, renal, or hepatic function
Chronic corticosteroid therapy
Clareo Health | A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer
